LPTX - Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?

• Shares of this small oncology company have risen by 45% over the past three months, yet are down 10% over the past month.
• One goal for both myself and readers is to cultivate the ability to rapidly identify highly asymmetric setups - LPTX fits that description after ESMO data in gastric/GEJ patients.
• I delve into the results, conference calls and explain what I saw that led me to prioritize gaining exposure to this name (including optionality in other cancers).
• Devil's advocate is that majority of China economics (the largest market opportunity for gastric cancer) are locked up by BeiGene. Additionally, pulmonary embolism is an AE to look out for.
• LPTX is a Buy. Catalyst pipeline for 2022 includes ASCO GI data in January, final PFS data at ASCO in June and trial starts for additional indications.

For further details see: